Microarray analysis of microrna expression in peripheral blood mononuclear cells of patients with polymyositis and dermatomyositis-Reference-Cited by-同舟云学术

Microarray analysis of microrna expression in peripheral blood mononuclear cells of patients with polymyositis and dermatomyositis

Published:2024-04-01 Issue:2 Volume:12 Page:170-176
ISSN:2224-4018
Container-title:Journal of Translational Internal Medicine
language:en
Short-container-title:

Author:

Shi Jia¹,Zhou Shuang¹,Zhao Jiuliang¹,Xu Dong¹,Huang Hui²,Li Mengtao¹,Tian Xinping¹,He Linrong³^ORCID,Wu Chanyuan¹^ORCID,Wang Qian¹,Zhao Yan¹,Zeng Xiaofeng¹

Affiliation:

1. Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China

2. Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China

3. China-Japan Friendship Hospital , Yinghua East Road, Chaoyang District , Beijing , China

Abstract

Abstract Background and Objectives MicroRNAs (miRNAs) represent a new class of biomarkers in the context of connective tissue disorders. The miRNA expression profiles in peripheral blood mononuclear cells (PBMCs) of patients with polymyositis (PM) and dermatomyositis (DM) have not been fully elucidated. The objective is to investigate miRNAs expression profile in PBMCs of patients with PM/DM. Methods Microarray technology was used to identify differentially expressed miRNAs in PBMCs obtained from 6 untreated PM/DM patients and 3 healthy controls (HCs). TaqMan-based stem-loop real-time PCR detection was used for validation in a cohort of 34 PM/DM patients and 20 HCs. Results Microarray analysis revealed 38 differentially expressed miRNAs (24 up-regulated and 14 down-regulated) in PM/DM patients compared to HCs. Four miRNAs (miR-320a, miR-335-3p, miR-34a-5p and miR-454-3p) were chosen for real-time PCR validation. The expression of miR-34a-5p was significantly upregulated in PM/DM group (P < 0.05). In subgroup analysis, miR-34a-5p was significantly upregulated in interstitial lung disease (ILD) group and DM group (P < 0.001). The level of SIRT1, a validated target of miR-34a, was significantly lower in PBMCs of PM/DM patients compared with HCs. Conclusions MiR-34a-5p may potentially participate in the pathogenesis of PM/DM through SIRT1, and may serve as a potential new biomarker for PM/DM-ILD.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.2478/jtim-2022-0055/pdf

Reference40 articles.

1. Marasco E, Cioffi E, Cometi L, Valentini V, Zanframundo G, Neri R, Cavagna L, Barsotti S. One year in review 2018: idiopathic inflammatory myopathies. Clin Exp Rheumatol 2018;36:937-47.

2. Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021;7:86.

3. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis 2015;35:3-11.

4. Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev 2013;113:6207-33.

5. Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact. Autoimmun Rev 2019;18:102391.